2023 year to date and third-quarter sales results
Ipsen has published its year to date and third-quarter sales results on 26 October 2023 at 7am CET.
Please find here the YTD 2023 sales presentation.
A conference call and webcast for investors and analysts was held on 26 October 2023. A recording is available below.
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With total sales of €3.0bn in FY 2022, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,300 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.
Craig Marks, Vice President, Investor Relations, +44 (0)7584 349 193
Nicolas Bogler, Senior Investor Relations Manager, +33 6 52 19 98 92
Amy Wolf, Vice President and Head of Corporate Brand Strategy and Communications, +41 79 576 07 23
Ioana Piscociu, Senior Manager, Global Media Relations, +33 6 69 09 12 96